Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML.

Blood cancer discovery - 3 Sept 2025

Renders Simon, Waclawiczek Alexander, Trumpp Andreas

Abstract excerpt

In a large retrospective multicenter study of patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax, Lachowiez and colleagues examine the interplay among genetic mutations, disease phenotype, and clinical outcomes. They show that within genetic subgroups-particularly NPM1 wild-type cases-monocytic differentiation is linked to poor treatment response and inferior long-term...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Genotype
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Nucleophosmin

Share to Phenotype

Share to Prognosis

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 40778677
DOI: 10.1158/2643-3230.BCD-25-0174
PMCID: PMC12405864

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML.PMID 40778677Read ↗

Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.Semantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsSemantic proximity Read ↗

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Semantic proximity Read ↗

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.Semantic proximity Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Group comparison based on genetic information reveals lineage-specific therapeutic vulnerabilities in acute myeloid leukemiaSemantic proximity Read ↗

Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.Semantic proximity Read ↗

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.Semantic proximity Read ↗

Multi‑omics factor analysis reveals a RAS mutant-like metabolically distinct AML subgroup resistant to venetoclaxSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.